Stock Market News3 weeks AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate Investor's Business Daily
AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.
The post AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate appeared first on Inv…